BioSpace News Archive

Business

22nd Century Files 2019 First Quarter Report and Announces Conference Call to Provide Business Update

22nd Century’s proposed VLN™ cigarettes continue to fall squarely within the nicotine range that public health officials anticipate will be mandated by the FDA.

May 7, 2019
·
12 min read
Business

Research Point Global and WuXi CDS to rebrand as WuXi Clinical – a client-centric CRO – at DIA 2019

The newly combined CRO specializes in collaborative partnering for global clinical trials.

May 7, 2019
·
3 min read
Absolute Antibody Launches Mouse Bispecific Antibody Reagents

Novel fully murine knob-into-hole antibodies for immunotherapy research and drug development

May 7, 2019
·
2 min read
Deals

Service Corporation International Announces Pricing of Senior Notes Offering

Service Corporation International announces that it has priced an underwritten public offering of $750 million aggregate principal amount of 5.125% Senior Notes due 2029.

May 7, 2019
·
6 min read
Business

DURECT Corporation Announces First Quarter 2019 Financial Results and Update of Programs

Live Webcast of Alcoholic Hepatitis KOL and Earnings Call on Wednesday, May 8th at 8:30 a.m. ET

May 7, 2019
·
16 min read
Job Trends

Population Health Study Goes Statewide As University Medical Center of Southern Nevada Serves As Host Site For Enrollment Of 25,000 More Nevadans

The study could expand to a quarter million people, making Nevada the only state in the U.S. to offer such a program

May 7, 2019
·
8 min read
Business

Two Clinical Studies with IBI301, a Biosimilar Candidate to Rituximab, Met Primary Endpoints

Innovent Biologics, Inc. and Eli Lilly and Company jointly announced that IBI301 which is sold under the brand name MabThera/Rituxan has met pre-defined primary endpoints in two randomized clinical trials comparing IBI301 to rituximab, namely: a phase III clinical trial in patients with diffuse large B-cell lymphoma and a pharmacokinetic study in patients with CD20-positive B-cell lymphoma.

May 7, 2019
·
6 min read
Pharm Country

Biohaven Announces Expanded Safety And Preliminary Preventive Efficacy Data From Ongoing Long-Term Safety Study, And Presents Case Reports Of Using Rimegepant To Successfully Treat Breakthrough Migraine Attacks In Patients Taking Preventive CGRP

Over 105,000 doses of rimegepant 75 mg have been administered in over 1,780 migraine patients in the long-term safety study to date

May 7, 2019
·
6 min read
Job Trends

DispatchHealth Closes On $33 Million in Growth Financing Led by Echo Health Ventures

On-demand health care company will expand complex medical services for high-acuity patients and rapidly launch in new cities

May 7, 2019
·
5 min read
Biotech Bay

Seeloz’ SCAPH Initiative Empowers Countries to Better Fulfill the United Nations’ Sustainable Development Goals

Seeloz Inc. announced the Supply Chain Automation for Public Health initiative to partner with countries managing public healthcare systems.

May 7, 2019
·
4 min read